Published in Clin Gastroenterol Hepatol on July 12, 2007
Drug-eluting Bead in Hepatocellular Carcinoma (REDEBUT) | NCT01332669
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology (2012) 2.19
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J (2009) 1.62
Transcatheter intraarterial therapies: rationale and overview. Radiology (2011) 1.59
Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol (2011) 1.48
Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Saudi J Gastroenterol (2015) 1.43
Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol (2010) 1.31
Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit (2011) 1.06
Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J (2010) 0.98
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol (2016) 0.97
Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol (2011) 0.95
Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol (2015) 0.95
Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol (2013) 0.94
Interventional therapies for hepatocellular carcinoma. Cancer Imaging (2012) 0.93
New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer (2012) 0.92
Development of "imageable" beads for transcatheter embolotherapy. J Vasc Interv Radiol (2010) 0.91
Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J Control Release (2012) 0.90
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. J Mater Sci Mater Med (2010) 0.89
Current status of embolic agents for liver tumor embolization. Int J Clin Oncol (2012) 0.89
Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging (2013) 0.88
Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials (2012) 0.87
Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol (2014) 0.86
Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. Korean J Hepatol (2011) 0.85
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res (2011) 0.84
Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One (2014) 0.83
Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol (2013) 0.82
Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Case Rep Oncol (2014) 0.81
Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol (2015) 0.81
Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol (2015) 0.80
Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med (2014) 0.79
Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging (2010) 0.78
Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry. J Oncol (2012) 0.78
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol (2015) 0.78
Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol (2015) 0.78
Transcatheter intra-arterial infusion of doxorubicin loaded porous magnetic nano-clusters with iodinated oil for the treatment of liver cancer. Biomaterials (2016) 0.77
Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Clin Mol Hepatol (2015) 0.77
Hepatic arterial therapy with drug-eluting beads in the management of metastatic pancreatic carcinoma to the liver: a multi-institutional registry. J Oncol (2012) 0.77
Alginate Microspheres Containing Temperature Sensitive Liposomes (TSL) for MR-Guided Embolization and Triggered Release of Doxorubicin. PLoS One (2015) 0.76
Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol (2015) 0.76
Drug-eluting beads in hepatocellular carcinoma. Therap Adv Gastroenterol (2017) 0.75
Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™. J Control Release (2017) 0.75
DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med (2015) 0.75
Embolotherapy in the management of hepatocellular carcinoma. Semin Intervent Radiol (2008) 0.75
A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads. Korean J Hepatol (2010) 0.75
Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. World J Radiol (2017) 0.75
Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Chin J Cancer Res (2015) 0.75
Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford) (2009) 0.75
Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol (2016) 0.75
Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol (2014) 0.75
What's New in Transarterial Therapies for Hepatocellular Carcinoma? Gastrointest Cancer Res (2012) 0.75
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw (2017) 0.75
Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol (2017) 0.75
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg (2013) 3.11
Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg (2006) 2.59
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver. Hepatology (2012) 2.47
Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res (2006) 2.32
11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med (2013) 2.29
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg (2011) 2.05
Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (2008) 2.02
Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg (2011) 2.01
Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg (2004) 1.99
Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. J Am Coll Surg (2005) 1.98
The national program for deceased organ donation in China. Transplantation (2013) 1.83
Pyogenic liver abscess: retrospective analysis of 80 cases over a 10-year period. J Gastroenterol Hepatol (2002) 1.82
High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg (2011) 1.79
Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg (2002) 1.77
Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways. Liver Transpl (2007) 1.69
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology (2010) 1.66
Comparison of early endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the management of acute biliary pancreatitis: a prospective randomized study. Clin Gastroenterol Hepatol (2005) 1.66
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl (2007) 1.58
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Working up donors for high-urgency and elective adult-to-adult live donor liver transplantation. Liver Transpl (2007) 1.54
External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg (2007) 1.54
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg (2013) 1.51
Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 1.50
Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl (2012) 1.49
Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int (2008) 1.46
Long-term biological consequences of donor right hepatectomy including the middle hepatic vein in adult-to-adult live donor liver transplantation. Liver Transpl (2006) 1.46
Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg (2002) 1.45
Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma. Am J Gastroenterol (2004) 1.45
Paired donor interchange to avoid ABO-incompatible living donor liver transplantation. Liver Transpl (2010) 1.45
Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology (2008) 1.44
Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol (2005) 1.41
DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem (2011) 1.40
Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg (2007) 1.38
Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology (2010) 1.34
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol (2007) 1.31
Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg (2007) 1.30
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res (2005) 1.29
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res (2006) 1.25
Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg (2004) 1.24
Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg (2002) 1.23
Liver transplantation for acute-on-chronic liver failure. Hepatol Int (2009) 1.23
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology (2006) 1.20
Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Ann Surg (2007) 1.19
Estimating liver weight of adults by body weight and gender. World J Gastroenterol (2006) 1.17
An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res (2009) 1.16
Risk factors for biliary complications after liver transplantation. Arch Surg (2004) 1.16
Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res (2005) 1.15
Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res (2010) 1.15
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res (2005) 1.15
Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation. Liver Transpl (2012) 1.14
Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. Biochem Biophys Res Commun (2004) 1.13
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl (2005) 1.10
Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res (2004) 1.09
Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol (2004) 1.08
Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One (2012) 1.08
Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res (2005) 1.07
Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg (2014) 1.07
Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl (2004) 1.06
The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg (2008) 1.05
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist (2011) 1.05
PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene (2004) 1.05
Hepatic resection for incidentaloma. J Gastrointest Surg (2004) 1.04
Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg (2007) 1.04
Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl (2011) 1.04
Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res (2002) 1.04
Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. Arch Surg (2007) 1.04
Comparison of systemic responses of radiofrequency ablation, cryotherapy, and surgical resection in a porcine liver model. Ann Surg Oncol (2004) 1.03
FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant (2005) 1.03
ATR dependent activation of Chk2. J Cell Physiol (2006) 1.03
Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol Carcinog (2007) 1.03
HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics (2013) 1.02
Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement. World J Surg (2004) 1.02
Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther (2005) 1.02
Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res (2006) 1.02
A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg (2008) 1.02
Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer (2011) 1.01
FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One (2012) 1.01
Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis (2004) 1.01